Last reviewed · How we verify
NCT06730685: PHILUCA
Sarcopenia and Cachexia in Patients With Lung Cancer
trial in Non-small Cell Lung Cancer (NSCLC) in 160 participants. Enrolling by invitation.
1 April 2027
Quick facts
| Lead sponsor | Zealand University Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 12 December 2024 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 April 2028 |
| Sites | 1 location across Denmark |
Conditions studied
- Non-small Cell Lung Cancer (NSCLC) — all drugs for Non-small Cell Lung Cancer (NSCLC) →
- Small Cell Lung Cancer (SCLC) — all drugs for Small Cell Lung Cancer (SCLC) →
Sponsor
Zealand University Hospital
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. It also aims to explore why some patients face challenges in completing their treatment. The findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06730685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07361497 — A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec · Phase 3 · recruiting
- NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT07291037 — Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N · Phase 3 · recruiting
- NCT07140016 — A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · Phase 1 · recruiting
Other Zealand University Hospital trials
Trials by the same sponsor.
- NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
- NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
- NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06730685 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06730685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing